[3,4-Dibenzoyloxy-6-[2-dec-9-enoxy-3,5-dihydroxy-6-[[3,4,5-tribenzoyloxy-6-(benzoyloxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxy-5-methyloxan-2-yl]methyl benzoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: [3,4-Dibenzoyloxy-6-[2-dec-9-enoxy-3,5-dihydroxy-6-[[3,4,5-tribenzoyloxy-6-(benzoyloxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxy-5-methyloxan-2-yl]methyl benzoate
• 英文别名: [3,4-dibenzoyloxy-6-[2-dec-9-enoxy-3,5-dihydroxy-6-[[3,4,5-tribenzoyloxy-6-(benzoyloxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxy-5-methyloxan-2-yl]methyl benzoate
• 化学式: C₇₈H₈₀O₂₂
• 分子量: 1369.5
• InChiKey: QOYGBRLTTDBCLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.1
• 重原子数：
  100
• 可旋转键数：
  38
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  280
• 氢给体数：
  2
• 氢受体数：
  22

文献信息

• TARGETING LIPIDS
  申请人：Tekmira Pharmaceuticals Corporation

  公开号：US20140179761A1

  公开（公告）日：2014-06-26

  The present invention provides targeting lipids of structure L 100 -linker-L 101 (CI), where L 100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L 101 is a ligand or —CH 2 CH 2 (OCH 2 CH 2 ) p O(CH 2 ) q CH 2 -ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

  本发明提供了结构为L100-连接体-L101(CI)的靶向脂质，其中L100是一种脂质、亲脂性、烷基、烯基或炔基，L101是一种配体或— (O )pO(CH2)q -配体，p为1-1000，q为1-20。此外，本发明还提供了递送治疗剂到细胞的组合物和方法。特别地，这些包括新型脂质和核酸-脂质颗粒，它们提供了核酸的高效封装和封装核酸的高效递送到体内细胞的方法。
• US9814777B2
  申请人：——

  公开号：US9814777B2

  公开（公告）日：2017-11-14